Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
Equillium, Inc. announced that new preclinical data for its investigational therapy EQ504 will be presented as posters at IMMUNOLOGY2026, highlighting EQ504's potential as a potent AhR modulator with multi-modal, non-immunosuppressive actions aimed at treating autoimmune and inflammatory disorders such as ulcerative colitis and inflammatory lung di…